Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection

Infection and Immunity

Volumn 80, Issue 2, 2012, Pages 875-882

  Roberts, April ^a   Mcglashan, Joanna ^a   Ibrahim, Al Abdulla ^b   Ling, Roger ^a   Denton, Harriet ^a   Green, Steve ^c   Coxon, Ruth ^b   Landon, John ^b   Shone, Clifford ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Newcastle Emlyn   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN A ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXIN B ANTIBODY; NEUTRALIZING ANTIBODY; TOXIN ANTIBODY; TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SCREENING; HAMSTER; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION PREVENTION; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; POST TREATMENT SURVIVAL; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CRICETINAE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; IMMUNIZATION, PASSIVE; SHEEP;

EID: 84857180090     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05684-11     Document Type: Article

References (42)

1. Ananthakrishnan AN. 2011. Clostridium difficile infection: epidemiology, risk factors and management. Nat. Rev. Gastroenterol. Hepatol. 8:17-26.
2. Babcock GJ, et al. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-6347.
3. Bartlett JG. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145:758-764.
4. Borriello SP. 1998. Pathogenesis of Clostridium difficile infection. J. Antimicrob. Chemother. 41(Suppl C):13-19.
5. Braun V, Hundsberger T, Leukel P, Sauerborn M, von Eichel-Streiber C. 1996. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 181:29-38.
6. Brazier JS. 2008. Clostridium difficile: from obscurity to superbug. Br. J. Biomed. Sci. 65:39-44.
7. Cartman ST, Heap JT, Kuehne SA, Cockayne A, Minton NP. 2010. The emergence of "hypervirulence" in Clostridium difficile. Int. J. Med. Microbiol. 300:387-395.
8. Dart RC, McNally J. 2001. Efficacy, safety, and use of snake antivenoms in the United States. Ann. Emerg. Med. 37:181-188.
9. Freeman J, Baines SD, Saxton K, Wilcox MH. 2007. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J. Antimicrob. Chemother. 60:83-91.
10. Gerding DN, Johnson S. 2010. Management of Clostridium difficile infection: thinking inside and outside the box. Clin. Infect. Dis. 51:1306-1313.
11. Giannasca PJ, et al. 1999. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect. Immun. 67:527-538.
12. Hussack G, et al. 2011. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J. Biol. Chem. 286:8961-8976.
13. Jank T, Aktories K. 2008. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol. 16:222-229.
14. Kink JA, Williams JA. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 66:2018-2025.
15. Kirby JM, et al. 2009. Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. J. Biol. Chem. 284:34666-34673.
16. Kuehne SA, et al. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713.
17. Libby JM, Wilkins TD. 1982. Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect. Immun. 35:374-376.
18. Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. 2005. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J. 46:258-268.
19. Lowy I, et al. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205.
20. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. 1991. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect. Immun. 59:2215-2218.
21. Lyras D, et al. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
22. McDonald LC, et al. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
23. Mitty RD, LaMont JT. 1994. Clostridium difficile diarrhea: pathogenesis, epidemiology, and treatment. Gastroenterologist 2:61-69.
24. Musher DM, et al. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590.
25. Nam HJ, et al. 2010. Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation. J. Biol. Chem. 285:32888-32896.
26. Navaneethan U. 2008. Clostridium difficile colitis: a silent epidemic in the United States. Minerva Gastroenterol. Dietol. 54:451-453.
27. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. 2007. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect. Control Hosp. Epidemiol. 28:1219-1227.
28. Pizon AF, Riley BD, LoVecchio F, Gill R. 2007. Safety and efficacy of Crotalidae polyvalent immune Fab in pediatric crotaline envenomations. Acad. Emerg. Med. 14:373-376.
29. Roberts AK, Shone CC. 2001. Modification of surface histidine residues Roberts et al. abolishes the cytotoxic activity of Clostridium difficile toxin A. Toxicon 39:325-333.
30. Rothman SW, et al. 1988. Immunochemical and structural similarities in toxin A and toxin B of Clostridium difficile shown by binding to monoclonal antibodies. Toxicon 26:583-597.
31. Rupnik M. 2008. Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol. Rev. 32:541-555.
32. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmée M. 1998. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J. Clin. Microbiol. 36:2240-2247.
33. Sambol SP, Tang JK, Merrigan MM, Johnson S, Gerding DN. 2001. Colonization for the prevention of Clostridium difficile disease in hamsters. J. Infect. Dis. 183:1760-1766.
34. Saunders MD, Kimmey MB. 2003. Colonic pseudo-obstruction: the dilated colon in the ICU. Semin. Gastrointest. Dis. 14:20-27.
35. Schaeffer TH, et al. 2010. Treatment of chronically digoxin-poisoned patients with a newer digoxin immune Fab: a retrospective study. J. Am. Osteopath. Assoc. 110:587-592.
36. Schwan C, et al. 2009. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog. 5:e1000626.
37. Shone CC, et al. 2009. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect. Immun. 77:2795-2801.
38. Sougioultzis S, et al. 2005. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128:764-770.
39. Stabler RA, et al. 2010. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol. 10:R102.
40. van Dissel JT, et al. 2005. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J. Med. Microbiol. 54:197-205.
41. Ward SJ, Douce G, Dougan G, Wren BW. 1999. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect. Immun. 67:5124-5132.
42. Weiss K. 2009. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int. J. Antimicrob. Agents 33:4-7.